KPV
A tripeptide fragment of alpha-MSH researched for potent anti-inflammatory signaling with minimal pigmentary activity.
What KPV is
KPV is the carboxyl-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone. Classical pharmacology work showed that this tiny fragment retains substantial anti-inflammatory activity associated with the parent hormone while avoiding much of the melanotropic baggage of full-length alpha-MSH.
Peer-reviewed studies have examined KPV in models of crystal-induced and cytokine-driven inflammation, keratinocyte signaling, and murine inflammatory bowel disease. Reviews of alpha-MSH-related peptides position KPV and related analogs as tool compounds for immunology and barrier-tissue research. Antimicrobial properties against selected organisms have also been explored in experimental systems.
Dosage education should emphasize that human standardized injectable regimens are not established the way they are for approved hormones. Ranges circulating in research-peptide communities are secondary references. This page uses research-use-only language and points readers to primary immunology papers for mechanism context.
How it works
KPV modulates inflammatory signaling with evidence for both melanocortin-related and receptor-independent actions in different experimental setups. Reported effects include reduced pro-inflammatory cytokine tone and interference with NF-kB-linked transcriptional programs in immune and epithelial cells. Because pigmentary MC1R-driven melanogenesis is largely dissociated from KPV's anti-inflammatory profile, researchers value it as a stripped-down probe of alpha-MSH immunomodulation. Barrier tissues, skin and gut mucosa, are recurring experimental contexts.
Who works with it, and what they are measuring
Immunologists and gastroenterology labs use KPV in colitis and peritonitis models. Dermatology researchers examine keratinocyte and skin inflammation pathways. Peptide chemists compare KPV with related analogs such as KdPT. The audience is inflammation-biology focused rather than metabolic-obesity focused.
What the research examines
Research areas, not results. A topic on this list is being studied, not settled.
How it appears in the literature
Taken from the methods sections of the cited work. Not a recommendation.
| Research context | Reported amount | Frequency | Route |
|---|---|---|---|
| Commonly cited secondary research-protocol ranges for subcutaneous KPV | 200 mcg – 500 mcg | daily | subcutaneous |
| Experimental IBD and inflammation models (route varies: oral, i.p., or other study-defined routes) | Not a fixed mcg value | study-defined | model-dependent |
Handling & storage
Keep lyophilized KPV cold, dry, and protected from light. Reconstitute with bacteriostatic water under clean technique, refrigerate, and use within supplier stability guidance for small peptides.
Notes on combined research
KPV is the component that distinguishes Klow from Glow when added to GHK-Cu + BPC-157 + TB-500. Researchers also examine it conceptually alongside other barrier-focused agents. Combination products still require independent dose math for KPV content.
KPV questions
Secondary research protocols commonly discuss roughly 200-500 mcg subcutaneously per day, but this is not a standardized approved regimen. Primary literature doses are model-specific. Use those papers for scientific work and treat community charts as provisional.
A 10 mg vial with 2 mL bac water yields 5 mg/mL (5,000 mcg/mL), so 0.05 mL delivers 250 mcg. Smaller peptides are easy to over-concentrate; pick a diluent volume that makes your target mcg land on whole insulin units.
Daily administration is the pattern most often repeated in informal research writeups. Split dosing appears less often than once-daily schedules. Confirm whether your blend already includes KPV before adding a standalone vial.
Example at 5 mg/mL: 4 units (0.04 mL) ~ 200 mcg; 5 units ~ 250 mcg; 10 units ~ 500 mcg on a U-100 syringe. Recalculate if your reconstitution differs.
In acute animal inflammation models, endpoints can be measured within hours to days. Chronic barrier-injury models run longer. Human timelines for research endpoints are not standardized on educational blogs.
As a three-amino-acid peptide, KPV is expected to clear quickly from plasma. Pharmacodynamic anti-inflammatory effects in tissues may outlast measurable plasma levels; quantitative human half-life data remain limited publicly.
Yes in the narrow sense that blend products already combine it with repair peptides. Scientifically, stacking should serve a hypothesis, for example inflammatory tone plus matrix repair, and each agent's mcg contribution must stay transparent.
Read the research yourself
These references were validated against the NCBI database. No citation appears here unless it resolves to a real paper.
- Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.PubMed
- alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs.PubMed
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.PubMed
- alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells.PubMed